Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting
This study assesses the effectiveness of nirsevimab, a monoclonal antibody, in preventing medically attended respiratory syncytial virus-lower respiratory tract infections (RSV-LRTI) in a large primary care network in Spain.
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus
Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory infection in young children.
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Conclusions
Conclusions by Peter Openshaw, Co-Chair of the the ESWI Respiratory Virus Summit 2024
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Science Policy Interface debate
How to ensure/prepare for access to immunisation programmes
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Rapporteur from the RSVVW’ 2024 meeting in Mumbai
By Ab Osterhaus, Host of the ESWI Respiratory Virus Summit 2024
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: What's in the pipeline?
Live attenuated vaccines; NIRSE-GAL: Evaluation of the effectiveness and impact of Nirsevimab in Galicia; and Therapeutics
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Early Career Scientists
ESWI Summit 2024: Early Career Scientists They each delivered a presentation introducing themselves and their ongoing work on RSV, bringing innovative ideas and making clear calls for action.
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Diagnostics and Point of Care Testing
Keynote Lecture by Dexter Wiseman, Imperial College London
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Burden of disease in older adults
Keynote Lecture by Stefan Gravenstein, Brown University
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Burden of disease in infants
Keynote Lecture by Simon Drysdale, St George's University Hospitals NHS Foundation Trust
In Utero Exposure to Maternal COVID-19 Vaccination and Offspring Neurodevelopment at 12 and 18 Months
Uptake of COVID-19 vaccines among pregnant individuals was hampered by safety concerns around potential risks to unborn children.
